1. |
易秋, 艳张, 林潮.原发性高血压流行病学研究进展.中华高血压杂志, 2010, 18(9):823-826.
|
2. |
陆再英, 钟南山.内科学.北京:人民卫生出版社, 2008:251.
|
3. |
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:analysis of worldwide data. Lancet, 2005, 365(9455):217-223.
|
4. |
中华人民共和国卫生部.中国居民营养与健康状况.中国心血管病研究杂, 2004, 2(12):919-922.
|
5. |
中国高血压防治指南修订委员会.中国高血压防治指南2010.中华心血管病杂志, 2011, 39(7):579-616.
|
6. |
王宁.原发性高血压的发病机制与临床治疗.中国医药指南, 2013, (33):570-571.
|
7. |
于汇民, 王兵, 刘国仗, 等.原发性高血压的病因及发病机制.新医学, 2003, 34(3):135-136.
|
8. |
杨克虎, 刘雅莉, 袁金秋, 等.发展和完善中的系统评价再评价.中国循证儿科杂志, 2011, 6(1):54-57.
|
9. |
刘雅莉, 袁金秋, 杨克虎, 等.系统评价再评价的制作方法简介及相关资料分析.中国循证儿科杂志, 2011, 6(1):58-64.
|
10. |
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure:the JNC 7 report. JAMA, 2003, 289(19):2560-2571.
|
11. |
Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR:a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7:10.
|
12. |
GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328(7454):1490.
|
13. |
曾宪涛, 冷卫东, 李胜, 等.如何正确理解及使用GRADE系统.中国循证医学杂志, 2011, 11(9):985-990.
|
14. |
陈新宇, 尹玲珑, 刘紫轩, 等.半夏白术天麻汤治疗原发性高血压临床疗效Meta分析.辽宁中医杂志, 2014, 41(2):196-199.
|
15. |
王琼.丹参注射液治疗高血压脑出血疗效与安全性的Meta分析.浙江大学, 2012.
|
16. |
郭意欣, 陈新林, 丘振文, 等.六味地黄丸联合西药治疗高血压病的Meta分析和系统评价.中国中医急症, 2013, 22(2):189-191.
|
17. |
周倩仪, 马楷奇, 郭意欣, 等.天麻钩藤饮联合卡托普利治疗原发性高血压的系统评价和Meta分析.安徽中医学院学报, 2013, 32(4):12-17.
|
18. |
董大幸, 姚松林, 余男, 等.天麻钩藤饮联合依那普利治疗原发性高血压系统评价和Meta分析.中国中医急症, 2011, 20(5):762-764.
|
19. |
任毅, 欧爱华, 林晓忠.中医药治疗原发性高血压随机对照试验的Meta分析.陕西中医, 2006, 27(7):794-796.
|
20. |
戴娟.中医药治疗原发性高血压的系统评价.中国中医药咨讯, 2010, 2(36):22-24.
|
21. |
杜浩, 戴小华.养血清脑颗粒治疗高血压伴随症状的Meta分析.安徽中医药大学学报, 2014, 33(1):8-11.
|
22. |
李东娜, 杨传华.中医药治疗老年单纯收缩期高血压临床疗效的Meta分析.辽宁中医杂志, 2012, 39(5):812-815.
|
23. |
Xiong X, Yang X, Liu W, et al. Banxia Baizhu Tianma Decoction for Essential Hypertension:A Systematic Review of Randomized Controlled Trials. Evid Based Complement Alternat Med, 2012, 2012:271462.
|
24. |
Wang J, Feng B, Yang X, et al. Tianma gouteng yin as adjunctive treatment for essential hypertension:systematic review of randomizedcontrolled trials. Evid Based Complement Alternat Med, 2013, 2013:706125.
|
25. |
Wu X, Jiang X. Systematic review and meta-analysis of randomized controlled trials on Tianmagouteng decoction in treatment of primary hypertension with liver Yang hyperactivity syndrome. J Tradit Chin Med, 2013, 33(1):15-18.
|
26. |
Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011.
|
27. |
Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR:a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology, 2007, 7(1):10.
|
28. |
郭新峰, 赖世隆.对中医药领域开展循证医学研究的几点看法.中国循证医学杂志, 2008, 8(1):10-12.
|
29. |
王俊文, 崔蒙, 赵英凯, 等.中医药领域循证医学发展建议.世界中医药, 2010, 05(5):305-307.
|
30. |
李静, 李幼平.不断完善与发展的Cochrane系统评价.中国循证医学杂志, 2008, 8(9):742-743.
|
31. |
Jadad AR, Cook DJ, Jones A. Methodology and reports of systematic reviews and meta-analysis:a comparison of Cochrane paper-based journals. JAMA, 1998, 280(3):278-280.
|
32. |
郭新峰, 朱泉, 赖世隆.替代指标和中间指标及其在中医药疗效评价研究中应用价值的思考.中国中西医结合杂志, 2005, 25(7):585-590.
|
33. |
Oliver MF, Heady JA, Morris JN, et al. For the Committeeof Principal Investigators. WHO cooperative trial of primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol:final mortality follow-up. Lancet, 1984, 2:600-604.
|